Have a feature idea you'd love to see implemented?
Let us know!
CLDX Celldex Therapeutics Inc
Price (delayed)
$26.69
Market cap
$1.77B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.75
Enterprise value
$1.73B
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which
Highlights
The company's gross profit has surged by 155% YoY and by 37% QoQ
Celldex Therapeutics's revenue has soared by 155% YoY and by 37% from the previous quarter
Celldex Therapeutics's equity has soared by 193% YoY but it has decreased by 3% from the previous quarter
CLDX's quick ratio has surged by 80% year-on-year but it is down by 8% since the previous quarter
Celldex Therapeutics's net income has decreased by 33% YoY and by 3.7% from the previous quarter
Key stats
What are the main financial stats of CLDX
Market
Valuations
Earnings
Shares outstanding
66.29M
Market cap
$1.77B
Enterprise value
$1.73B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.16
Price to sales (P/S)
212.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
208.25
Revenue
$8.3M
EBIT
-$150.22M
EBITDA
-$147.12M
Free cash flow
-$122.93M
Per share
Balance sheet
Liquidity
EPS
-$2.75
Free cash flow per share
-$1.86
Book value per share
$12.34
Revenue per share
$0.13
TBVPS
$12.4
Total assets
$845.59M
Total liabilities
$31.93M
Debt
$2.39M
Equity
$813.66M
Working capital
$784.32M
Debt to equity
0
Current ratio
29.36
Quick ratio
29.06
Net debt/EBITDA
0.27
Margins
Efficiency
Dividend
EBITDA margin
-1,772.1%
Gross margin
100%
Net margin
-1,809.4%
Operating margin
-2,117.5%
Return on assets
-24.4%
Return on equity
-25.8%
Return on invested capital
-29.5%
Return on capital employed
-18.4%
Return on sales
-1,809.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLDX stock price
How has the Celldex Therapeutics stock price performed over time
Intraday
-0.63%
1 week
-6.91%
1 month
-21.48%
1 year
17.58%
YTD
-32.7%
QTD
-21.48%
Financial performance
How have Celldex Therapeutics's revenue and profit performed over time
Revenue
$8.3M
Gross profit
$8.3M
Operating income
-$175.79M
Net income
-$150.22M
Gross margin
100%
Net margin
-1,809.4%
The company's gross profit has surged by 155% YoY and by 37% QoQ
Celldex Therapeutics's revenue has soared by 155% YoY and by 37% from the previous quarter
The net margin has increased by 48% YoY and by 24% QoQ
Celldex Therapeutics's operating income has decreased by 45% YoY and by 8% QoQ
Growth
What is Celldex Therapeutics's growth rate over time
Valuation
What is Celldex Therapeutics stock price valuation
P/E
N/A
P/B
2.16
P/S
212.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
208.25
CLDX's EPS is down by 14% YoY but it is up by 3.8% from the previous quarter
Celldex Therapeutics's equity has soared by 193% YoY but it has decreased by 3% from the previous quarter
The P/B is 44% lower than the 5-year quarterly average of 3.9 and 44% lower than the last 4 quarters average of 3.9
Celldex Therapeutics's revenue has soared by 155% YoY and by 37% from the previous quarter
CLDX's price to sales (P/S) is 46% lower than its 5-year quarterly average of 398.9 and 33% lower than its last 4 quarters average of 319.6
Efficiency
How efficient is Celldex Therapeutics business performance
CLDX's ROS is up by 48% YoY and by 24% from the previous quarter
Celldex Therapeutics's ROIC has increased by 31% YoY and by 23% from the previous quarter
The ROE has grown by 29% YoY and by 20% from the previous quarter
The ROA is up by 27% YoY and by 19% QoQ
Dividends
What is CLDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLDX.
Financial health
How did Celldex Therapeutics financials performed over time
Celldex Therapeutics's total assets has soared by 183% YoY but it has decreased by 2.7% from the previous quarter
CLDX's quick ratio has surged by 80% year-on-year but it is down by 8% since the previous quarter
The debt is 100% lower than the equity
Celldex Therapeutics's equity has soared by 193% YoY but it has decreased by 3% from the previous quarter
CLDX's debt to equity has dropped by 100% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.